Heparinoid- low molecular weight heparin sodium has a lasting anti-thrombotic effect, is a new drug for the prevention and treatment of thromboembolic diseases. After intravenous drug on rabbit, seven kinds of coagulation indexes determination in vitro thrombosis test and three kinds of anti thrombosis experiment in mice, show that ji Lin has anticoagulant, resisting thrombosis, like heparin, ji Lin first and antithrombin Ⅲ (AT Ⅲ) and its compounds, strengthen antithrombin Ⅲ inactivated of thrombin and Xa factor, However, due to the short molecular chain, low molecular weight heparin has no part to bind to thrombin, so it cannot strengthen antithrombin Ⅲ shows strong anti-Xa factor activity on thrombin inactivation, and has little effect on thrombin. Compared with heparin, the anti-Xa factor activity was higher than that of heparin, but the effect of prolonging APTT was not obvious, so the anti-Xa /APTT ratio was higher than that of heparin, and the duration of the effect of low molecular weight heparin on Xa factor was longer than that of influencing APTT. The results of quality control showed that the ratio of anti-Xa activity to anti-Ⅱ activity was 3 ~ 4, which was higher than that of normal heparin (1∶1).

　　Therefore, it is less likely to cause bleeding than heparin. At the same time, geperoline can promote the release of vascular t-PA, play a fibrinolytic role, bind to vascular endothelial cells, protect endothelial cells, enhance the anti-thrombotic effect, and have less influence on platelet function and lipid metabolism than heparin. The main cause of death was intrathoracic, lung, stomach and intestinal bleeding. The main cause of death was intrathoracic, lung, stomach and intestinal bleeding.

　　Dorsal SC (male mice) ± mean confidence limit =9412.39±2031.89mg/kg when reduced to anti-XAIU =970640.76±17678.76IU/kg The main causes of death were injection site bleeding, lung and gastrointestinal bleeding. Subacute, chronic, reproductive toxicity and mutagenesis studies have shown that no toxic reactions were found when the dosage was more than 2 times the therapeutic dose. However, at high doses, a local hematoma may develop subcutaneously at the injection site.